Luspatercept is a drug for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene. Luspatercept-aamt is a recombinant fusion protein that binds multiple endogenous Transforming growth factor-beta (TGF-β) superfamily ligands, reducing Smad2 / 3 signalling.
The drug is a first-in-class erythroid maturation agent (EMA) that promotes late-stage erythroid maturation or differentiation of red blood cells. The U.S. Food and Drug Administration awarded orphan drug status in 2013 and fast track designation in 2015 for both indications.
“ACE-536 (Luspatercept Mechanism of Action) Drug Insight and Market Forecast — 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the ACE-536 (Luspatercept) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product.
The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ACE-536 (Luspatercept) Analytical Perspective by DelveInsight
In-depth ACE-536 (Luspatercept) Market Assessment
This report provides a detailed market assessment of ACE-536 (Luspatercept) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.
ACE-536 (Luspatercept) Clinical Assessment
The report provides the clinical trials information of ACE-536 (Luspatercept) covering trial interventions, trial conditions, trial status, start and completion dates.
Source:- Luspatercept Mechanism of Action
Comments